New drug combo aims to slow advanced lung cancer in patients with EGFR mutations

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced disease will be randomly assigned to receive either the combination or osimertinib alone. The main goal is to see if the combination delays cancer progression.